GSK ready to kick the tires of any Pfizer OTC divestiture
LONDON — If Pfizer follows through with its announcement last week to potentially place its consumer business up for sale, GlaxoSmithKline, presently the third-largest OTC seller in the U.S. marketplace, would certainly take a look at it, the company's CEO shared Wednesday morning.
"We did say we'd be potentially interested in building up our consumer business; it's a business we like. We're a world leader in consumer healthcare and have a demonstrated track record of successful integrations," GSK CEO Emma Walmsley, explained to investors during the comany's quarterly conference call.
"So you would expect us to look at any assets that compliment our portfolio from a power brand or geographic footprint point of view," she said. "We've been looking at it, but they only announced the process last week, so it's a bit premature and it's not even confirmed for sale to discuss in any detail if and how."
But one can wonder.
The biggest impact of any potential acquisition of Pfizer's consumer business by GlaxoSmithKline would be that company's entree into VMS. Pfizer is the market leader in liquid vitamins through its 2012 acquisition of Alacer and its Emergen-C business. For the 52 weeks ended Sept. 10, Alacer posted $168.1 million in liquid vitamin sales across total U.S. multi-outlet, according to IRI, on growth of 9.1%. And Pfizer's multivitamin Centrum brand, which contributed to $282.1 million in multivitamin sales on growth of 7.1%, is second only to Bayer's One-A-Day in that category.
The rest of Pfizer's brands would add to GlaxoSmithKline's already considerable heft in OTC: Pfizer fields Dimetapp and Robitussin in cough/cold to GlaxoSmithKline's Triaminic and Theraflu; Pfizer wields Nexium 24HR in the antacid space against GlaxoSmithKline's venerable Tums brand; in pain, it's Pfizer's Advil vs. GlaxoSmithKline's Excedrin (though the external analgesic Thermacare line of adhesive heat would be additive to GlaxoSmithKline here).
A combination of GlaxoSmithKline, its joint venture with Novartis' consumer healthcare brands and the onboarding of Pfizer's consumer business would leapfrog the company over both Bayer and Johnson & Johnson in becoming the clear market leader. According to Kline Group, based on 2016 sales Bayer had an 8.2% market share, Johnson & Johnson 7.5% and GlaxoSmithKline Consumer Healthcare 6.5%. The addition of Pfizer's 6.2% would concievably bring the combined GlaxoSmithKline business to a marketshare of 12.7%.
GlaxoSmithKline on Wednesday posted $2.6 billion in global sales, representing growth of 5%. In the U.S., GlaxoSmithKline Consumer Healthcare generated $568.7 million on growth of 1%. Private label competition across GlaxoSmithKline Consumer Healthcare's Flonase offset strong performance by the company's OTC power brands.
Without the infusion of Pfizer's OTC business, GlaxoSmithKline Consumer Healthcare expects low to middle single-digit growth through 2020, including a comparable 1% growth into next year as store brand versions of Flonase continue to impact that business.
DSNTV: EZC Pak brings immune support from doctor’s office to OTC space
There currently are roughly 2 million drug-resistant infections in the United States, and one of the contributing factors to their growth has been overuse of antibiotics, and 94% of doctors are concerned about the overuse of antibiotics. In light of this problem, Los Angeles-based EZC Pak has helped physicians reduce the number of antibiotics prescribed during initial visits, and is setting its sights on the consumer health market.
EZC Pak creator and CEO Dr. Sarath Malepati took the EZC Active Pak to San Diego and the National Association of Chain Drug Stores Total Store Expo, where Drug Store News caught up with him to discuss the need for a physician-formulated immune support pack and how EZC Pak is using it to move into the company’s next phase.
“I consider this product my baby — we worked very hard on this and we’re very much excited as a team to be bringing this product to market,” Malepati said.
The product already turned heads this year at the ECRM Cough/Cold, Analgesics and Allergy EPPS, where the product won the DSN/ECRM Buyers’ Choice Award.
OneTouch research finds combination of BGM, diabetes app most effective
CHESTERBROOK, Pa. — New research published in two leading diabetes journals demonstrated accuracy and reliability of the OneTouch Verio Flex blood glucose monitoring system, and when the system was used with the OneTouch Reveal mobile app, it was associated with significant improvements in glycemic control.
In a study just published in the Journal of Diabetes Science and Technology, leading experts in self-monitoring of blood glucose found that the "new system showed a high level of measurement accuracy."
Another study published in the August issue of JMIR Diabetes randomly assigned 128 adults with sub-optimally controlled type 1 and type 2 diabetes based on A1C into two groups: One group switched from their current blood glucose monitoring meter to the OneTouch Verio Flex blood glucose monitoring system; the other group switched from their current meter to the OneTouch Verio Flex blood glucose monitoring system combined with the OneTouch Reveal mobile app.
Results suggested improved glycemic control at 12 and 24 weeks in both the meter-only and meter-plus-mobile-app groups compared to baseline. According to the study, 88% of the subjects reported the Color Range Indicator on the OneTouch Verio Flex blood glucose monitoring system together with the OneTouch Reveal mobile app "could help me stay on track between visits to my health care provider." Improvements using the app were greatest in the participants with type 2 diabetes and those who received the highest number of healthcare provider text messages.
"Self-monitoring of blood glucose is still the most accurate, effective and accessible way people with diabetes can track their blood sugars," commented Brian Levy, chief medical officer, LifeScan. "With the OneTouch Verio Flex blood glucose monitoring system, we are proud to offer people with diabetes and their care teams a very accurate system that they know they can trust. Building on that accuracy, we now have our interconnected diabetes management OneTouch Reveal system that changes the way patients see their blood sugar. This enables both patients and physicians to use that information to make meaningful decisions about their diabetes management."